Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data MYRIAD GENETICS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
771
744
851
639
557
691
678
753
838
825
Cost of revenue
145
202
236
252
248
Gross profit
626
476
517
585
577
Research and development
74.4
70.8
85.9
77.2
73.3
81.9
85.4
88.7
113
107
Selling, general and administrative
440
435
557
507
497
538
515
573
Selling and marketing
267
289
284
281
General and administrative
248
284
276
257
Operating expenses
617
774
709
964
Operating income
44
122
7.6
-232
-290
-191
-141
-257
-124
-387
Interest expense
6
3.2
12
10.8
11.2
6.6
3.2
2.9
2.8
10.5
Interest income
1.2
1.8
3.2
3
2
0.7
2.6
2.5
1.7
1.8
Other non-operating income
-7.8
-1.8
-7.6
8.4
6.1
133
0
-4.8
0
-7.9
Pre-tax income
36.2
120
0
-223
-284
-57.1
-141
-262
-124
-395
Income tax
19
-13
-4.4
-23.7
-59.9
-29.9
-28.6
1.1
3.8
-29.2
Net income to minority interests
-0.2
-0.2
-0.2
-0.1
-0.1
0
0
Net income
17.4
133
4.6
-200
-224
-27.2
-112
-263
-127
-366
EBITDA
92.3
176
80.6
-160
-128
-87.9
-196
-62.3
-334
EPS, basic
0.25
1.92
0.06
-2.69
-2.99
-0.35
-1.39
-3.18
-1.41
-3.95
EPS, diluted
0.25
1.85
0.06
-2.69
-2.99
-0.35
-1.39
-3.18
-1.41
-3.95
Shares, basic (weighted)
68.3
69.4
73.5
74.3
74.8
78
80.6
82.8
90.6
92.6
Shares, diluted (weighted)
68.8
72
76
74.3
74.8
78
80.6
82.8
90.6
92.6
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
102
111
93.2
164
117
257
56.9
132
102
150
Short-term investments
48.3
69.7
43.7
54.1
33.7
81.4
58
8.8
0
Receivables
89.2
99.5
134
68.1
89.5
91.3
102
114
121
115
Inventory
42.2
34.3
31.4
29.1
27.1
15.3
20.1
22
27.5
30.6
Other current assets
13.7
21
20.4
19.4
30.5
25.1
Total current assets
302
328
349
332
389
485
275
314
298
333
Property, plant and equipment
51.1
43.2
57.3
37
40.7
43.5
83.4
119
117
114
Lease right-of-use assets
0
66
59.7
81.8
104
61.6
55
49.4
Goodwill
316
319
417
328
329
239
287
287
286
51.6
Intangible assets
492
455
685
605
577
404
380
350
262
153
Long-term investments
48.5
30.7
54.9
37
21
59
54.8
0
Other non-current assets
0
0
2.3
8.3
15.5
15.4
8.5
5.6
Total assets
1,209
1,175
1,563
1,405
1,419
1,321
1,199
1,147
1,028
707
Accounts payable
22
26
33.3
21.7
20.5
29.6
28.8
25.8
32.3
30
Accrued liabilities
65.6
68.3
82.3
79
79.1
162
94.3
114
119
96.9
Deferred revenue
2.6
2.6
2.2
32.8
32.7
5.2
0.6
0.5
Short-term debt
0
0
Total current liabilities
218
102
118
147
146
204
137
156
164
134
Long-term debt
99.1
9.3
234
224
225
0
0
38.5
39.6
120
Lease liabilities
0
56.9
50.6
79.3
131
97.4
87.9
83
Other non-current liabilities
7.2
6.3
18.2
8
14.7
5.6
18
41.3
2.2
1.9
Total liabilities
441
209
474
486
538
353
313
363
327
339
Total debt
99.1
9.3
234
224
225
0
0
38.5
39.6
120
Paid-in capital
851
915
1,068
1,097
1,110
1,226
1,260
1,416
1,458
1,489
Retained earnings
-79.2
54.1
25.6
-174
-227
-254
-366
-630
-757
-1,123
Other comprehensive income
-5.5
-4.1
-5.4
-5.2
-2.3
-5.1
-8.9
-3.7
-0.8
0.8
Shareholders' equity
768
966
1,089
918
881
968
886
783
701
368
Minority interests
-0.4
0
0
0
0
0
Total equity
767
966
1,089
918
881
968
886
783
701
368
Total liabilities and equity
1,209
1,175
1,563
1,405
1,419
1,321
1,199
1,147
1,028
707
Shares outstanding
68.4
70.6
73.5
74.7
75.4
80
81.2
89.9
91.3
93.5
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
17.2
133
4.4
-200
-224
-27.2
-112
-263
-127
-366
Depreciation and amortization
48.3
54.4
73
72
62.8
52.7
61.9
61.2
53.7
Stock-based compensation
29.9
27.1
33.5
25.2
36.3
38.1
40.7
49.8
35.2
Deferred income tax
1.1
-22.9
19.7
-55.7
-31.7
-30.5
-4.3
-2.3
1.4
Change in receivables
0.5
-9.1
-18.2
64
-8.8
-10.3
-12.5
-8.7
6.2
Change in inventory
-1.2
7.9
8
1.6
1.6
-2.9
-1.8
-6.2
-3.2
Change in payables
-3
4
1.1
-10.7
9.2
-3.5
-3.7
4.7
-1.4
Cash from operations
106
116
83.7
60.7
18.6
-106
-111
-8.7
1.8
Capital expenditures
-6.1
-8.4
-8.6
-10.2
-18
-45.3
Acquisitions
-216
0
-279
0
0
-57.2
0
0
Purchases of investments
-87.5
-80.9
-78.5
-60.8
-148
-103
0
0
Sales and maturities of investments
2.6
77.7
79.2
3.4
8.3
28.4
90.4
9
0
Cash from investing
-146
-11.6
-286
19.3
274
-77.5
31.9
-11.9
-27.4
Share buybacks
-31.6
0
-50
0
0
Cash from financing
71.8
-95
182
-10
-151
-8
153
-7.4
64.2
Exchange rate effect
-0.8
2.7
0.5
-0.6
-0.6
0.6
-1
0.8
Net change in cash
33.9
8.5
-17.7
70.5
142
-192
74.5
-29
39.4
Free cash flow
100
108
75.1
50.5
0.6
-152
Interest paid
5.6
3
11.6
9.5
4.4
0
1.4
1.9
8.4
Income taxes paid
12.3
11.7
6.5
1
4.6
1.8
1.9
2.7
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.17 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
68.8%
Gross profit / revenue.
Operating margin
-12.2%
Operating income / revenue.
EBITDA margin
-7.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-13.9%
Pre-tax income / revenue.
Net margin
-14.0%
Net income / revenue.
Operating cash flow margin
1.0%
Cash from operations / revenue.
Return on equity (ROE)
-37.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-17.6%
Net income / average total assets.
Return on invested capital (ROIC)
-25.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
13.1%
Research and development expense / revenue.
Stock-based pay / revenue
3.6%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
4.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-1.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
6.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
8.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-1.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
6.6%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-47.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-25.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-16.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-31.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-16.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-13.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
2.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
4.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.21x
Current assets / current liabilities.
Quick ratio
1.72x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.88x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.40x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
18.9%
Total debt / total assets.
Liabilities / assets
52.4%
Total liabilities / total assets.
Net debt
$5.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.19
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$8.51
Revenue / diluted weighted shares.
Operating cash flow per share
$0.08
Cash from operations / diluted weighted shares.
Book value per share
$3.18
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.49x
Market cap / revenue.
P/B
1.31x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.39x
Market cap / tangible book value, when positive.
P/OCF
51.8x
Market cap / cash from operations, when positive.
EV/Sales
0.50x
Enterprise value / revenue.
Earnings yield
-28.2%
Net income / market cap (the inverse of P/E).
What was MYRIAD GENETICS INC's revenue in fiscal 2025?
MYRIAD GENETICS INC reported revenue of $824.5M for fiscal 2025, 1.6% lower than the year before.
Was MYRIAD GENETICS INC profitable in fiscal 2025?
No. It reported a net loss of $365.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.